Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7221MR)

This product GTTS-WQ7221MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ7221MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13189MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ15309MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ7035MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ1479MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ7385MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ15430MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ10123MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LAG-525
GTTS-WQ2254MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALX-0171
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW